Single chain antibodies directed to pancreatic beta cells
- 詳細技術說明
- The intellectual property relates to beta- or alpha-cell specific single chain antibodies (SCAs) that enable the specific and non-invasive transport of a selected therapeutic agent to pancreatic islet - or α-cells.
- *Abstract
-
In one aspect, fusion proteins comprising a single chain antibodies (SCA) specific for pancreatic beta- cells and a NEMO binding domain (NBD) [SCA B1-NBD fusion protein] protects islets against the deleterious effects of IL-1beta in vitro, diabetogenic agents in vivo, and enables nearly complete protection from developing diabetes in multiple low dose streptozotocin (MLDS) treated mice. Taken together, the SCA B1-NBD chimera affords highly specific, targeted therapy to beta-cells, and provides a novel, non-invasive strategy of SCA-mediated beta-cell specific delivery with potential to prevent cell death.
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
